HARA-B Cells

Unit

3 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Lung cancer cell lines

Organism

Human

Donor History

Lung squamous cell carcinoma

Growth Properties

Adherent

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/HARA-B-Cells/300465

SKU: 300465 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

The HARA-B cell line is derived from human squamous cell carcinoma of the lung, specifically established from metastatic bone tissue in a mouse model. This cell line is a secondary development from the original HARA cell line and is characterized by its high expression of parathyroid hormone-related protein (PTHrP), which plays a significant role in the extensive bone metastasis observed in these cells. The HARA-B line has been instrumental in studying the mechanisms of bone metastasis associated with lung cancer.
Scientific studies involving HARA-B often focus on its utility in modeling hypercalcemia, a common paraneoplastic syndrome associated with certain cancers, including lung cancer. The hypercalcemia in this model is induced by hypodermic transplantation of the cells, providing a valuable tool for understanding the interactions between cancer cells and bone cells, as well as the pathways that lead to bone degradation and calcium release. This cell line helps researchers investigate potential therapeutic strategies to mitigate bone metastasis and associated complications in lung cancer patients.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.